Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith S Reisinger

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
The Pediatric Infectious Disease Journal|March 12, 2004
Concomitant administration of a bivalent Haemophilus influenzae type b-hepatitis B vaccine, measles-mumps-rubella vaccine and varicella vaccine: safety, tolerability and immunogenicityTeresa M Hesley, Keith S Reisinger, Bradley J Sullivan, et al.
Pediatrics|May 5, 2010
Safety, tolerability, and immunogenicity of gardasil given concomitantly with Menactra and AdacelKeith S Reisinger, Stan L Block, Michelle Collins-Ogle, et al.
Vaccine|March 23, 2015
M-M-R(®)II manufactured using recombinant human albumin (rHA) and M-M-R(®)II manufactured using human serum albumin (HSA) exhibit similar safety and immunogenicity profiles when administered as a 2-dose regimen to healthy childrenRichard T Wiedmann, Keith S Reisinger, Jonathan Hartzel, et al.
Vaccine|January 10, 2012
Safety and immunogenicity of a modified process hepatitis B vaccine in healthy neonatesGianmaria Minervini, Barbara J McCarson, Keith S Reisinger, et al.
Human Vaccines|November 4, 2011
Safety and tolerability of zoster vaccine in adults ≥60 years oldAlexander V Murray, Keith S Reisinger, Boris Kerzner, et al.
The Pediatric Infectious Disease Journal|September 28, 2002
Impact of a birth dose of hepatitis B vaccine on the reactogenicity and immunogenicity of diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b combination vaccinationMichael E Pichichero, Mark M Blatter, Keith S Reisinger, et al.
Pediatrics|February 3, 2006
A combination measles, mumps, rubella, and varicella vaccine (ProQuad) given to 4- to 6-year-old healthy children vaccinated previously with M-M-RII and VarivaxKeith S Reisinger, Michelle L Hoffman Brown, Jin Xu, et al.
The Pediatric Infectious Disease Journal|December 3, 2009
Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) l1 virus-like particle vaccineStan L Block, Darron R Brown, Archana Chatterjee, et al.
The Pediatric Infectious Disease Journal|May 9, 2007
Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trialKeith S Reisinger, Stan L Block, Eduardo Lazcano-Ponce, et al.
Pediatrics|November 3, 2006
Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult womenStan L Block, Terry Nolan, Carlos Sattler, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
The Pediatric Infectious Disease Journal|March 12, 2004
Concomitant administration of a bivalent Haemophilus influenzae type b-hepatitis B vaccine, measles-mumps-rubella vaccine and varicella vaccine: safety, tolerability and immunogenicityTeresa M Hesley, Keith S Reisinger, Bradley J Sullivan, et al.
Pediatrics|May 5, 2010
Safety, tolerability, and immunogenicity of gardasil given concomitantly with Menactra and AdacelKeith S Reisinger, Stan L Block, Michelle Collins-Ogle, et al.
Vaccine|March 23, 2015
M-M-R(®)II manufactured using recombinant human albumin (rHA) and M-M-R(®)II manufactured using human serum albumin (HSA) exhibit similar safety and immunogenicity profiles when administered as a 2-dose regimen to healthy childrenRichard T Wiedmann, Keith S Reisinger, Jonathan Hartzel, et al.
Vaccine|January 10, 2012
Safety and immunogenicity of a modified process hepatitis B vaccine in healthy neonatesGianmaria Minervini, Barbara J McCarson, Keith S Reisinger, et al.
Human Vaccines|November 4, 2011
Safety and tolerability of zoster vaccine in adults ≥60 years oldAlexander V Murray, Keith S Reisinger, Boris Kerzner, et al.
The Pediatric Infectious Disease Journal|September 28, 2002
Impact of a birth dose of hepatitis B vaccine on the reactogenicity and immunogenicity of diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b combination vaccinationMichael E Pichichero, Mark M Blatter, Keith S Reisinger, et al.
Pediatrics|February 3, 2006
A combination measles, mumps, rubella, and varicella vaccine (ProQuad) given to 4- to 6-year-old healthy children vaccinated previously with M-M-RII and VarivaxKeith S Reisinger, Michelle L Hoffman Brown, Jin Xu, et al.
The Pediatric Infectious Disease Journal|December 3, 2009
Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) l1 virus-like particle vaccineStan L Block, Darron R Brown, Archana Chatterjee, et al.
The Pediatric Infectious Disease Journal|May 9, 2007
Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trialKeith S Reisinger, Stan L Block, Eduardo Lazcano-Ponce, et al.
Pediatrics|November 3, 2006
Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult womenStan L Block, Terry Nolan, Carlos Sattler, et al.
Pageof 3